Multicenter Phase I Open-label Dose-escalation Vaccine Trial of dHER2 Protein With AS15 Adjuvant in HER2-overexpressing Patients With High-risk Breast Cancer.
Phase of Trial: Phase I
Latest Information Update: 18 May 2017
At a glance
- Drugs Cancer vaccine HER-2 neu (Primary) ; AS15
- Indications Breast cancer
- Focus Adverse reactions
- Sponsors GlaxoSmithKline
- 10 Jun 2017 Biomarkers information updated
- 30 Sep 2011 Actual initiation date changed from Jan 2003 to Mar 2003 as reported by ClinicalTrials.gov.
- 30 Sep 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.